Pharma BD Deal Intelligence
A slow-burn immuno-oncology bet still in the balance: AstraZeneca's expanded deal for Innate Pharma's monalizumab paid up to $1.275B but the lead Phase 3 (INTERLINK-1) failed on futility in 2022, leaving the program's fate riding entirely on the PACIFIC-9 lung cancer readout expected in H2 2026.
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma, obtaining full oncology rights to monalizumab.
AstraZeneca to discontinue the Phase 3 INTERLINK-1 study of monalizumab plus cetuximab in R/M HNSCC after the futility interim analysis did not meet a…
Innate Pharma SA Form 6-K Q1 2026 business update and financial results (exhibit 99.1).
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
AstraZeneca expanded its immuno-oncology collaboration with Innate Pharma on 23 October 2018, obtaining full global oncology rights to monalizumab, a first-in-class anti-NKG2A antibody (NK/CD8 T-cell checkpoint). The multi-part deal comprised: (1) a $100M payment for monalizumab rights with up to $1.275B in total potential payments; (2) $50M upfront for a co-development option on IPH5201 (anti-CD39); and (3) $20M for license options on four preclinical molecules. For commercialized products AstraZeneca books sales and pays Innate double-digit to mid-teen royalties globally, with a 50:50 profit share in Europe. POST-DEAL ARC: A $50M milestone was triggered when the first patient was dosed in the monalizumab Phase 3 lung-cancer program. In August 2022 AstraZeneca discontinued the Phase 3 INTERLINK-1 trial (monalizumab + cetuximab in recurrent/metastatic head-and-neck cancer) after a futility interim analysis missed its pre-defined efficacy threshold. Monalizumab's value now hinges on the pivotal Phase 3 PACIFIC-9 trial (durvalumab + monalizumab or oleclumab in unresectable Stage III NSCLC), whose enrollment is complete with a data readout expected in H2 2026. On the optioned asset, IPH5201 (anti-CD39) reported positive MATISSE Phase 2 interim results at the AACR 2026 plenary (April 2026): pathological complete response of 35.7% in PD-L1>=1% and 50% in PD-L1>=50% resectable NSCLC, supporting continued study.
1.9M US cases/yr · $200.0B Global oncology market
Solid tumors encompass all non-hematologic cancers. IO checkpoint inhibitors, targeted therapies, and ADCs have transformed treatment across multiple tumor types. Pan-tumor approvals (e.g., MSI-H, NTRK) enable biomarker-driven approaches.
IO combinations, ADCs, and bispecifics driving growth. Tumor-agnostic approvals expanding. Key platforms: Merck (Keytruda), BMS (Opdivo), Roche (Tecentriq), Daiichi Sankyo/AZ (Enhertu).
200K US cases/yr · $30.0B Global NSCLC therapeutics
NSCLC accounts for ~85% of lung cancers. Treatment has been revolutionized by immunotherapy and targeted therapies for driver mutations (EGFR, ALK, ROS1, KRAS G12C). Checkpoint inhibitors are standard first-line for most patients without actionable mutations.
No driver mutation: pembrolizumab +/- chemo. EGFR+: osimertinib. ALK+: alectinib, lorlatinib. KRAS G12C: sotorasib. Key players: Merck (Keytruda $25B+), Roche (Tecentriq), AZ (Tagrisso $5B+, Imfinzi), Pfizer (Lorbrena), Amgen (Lumakras).
66K US cases/yr · $3.0B Global HNSCC therapeutics
HNSCC is driven by tobacco/alcohol or HPV infection. Pembrolizumab has become standard first-line for recurrent/metastatic disease.
Recurrent/metastatic: pembrolizumab +/- chemo (KEYNOTE-048). Locally advanced: cisplatin + radiation. Key players: Merck (Keytruda), BMS (Opdivo).
AZ paid $100M for full oncology rights to monalizumab (anti-NKG2A) plus IPH5201 (anti-CD39).
Futility interim analysis of monalizumab + cetuximab in recurrent/metastatic HNSCC missed the pre-defined efficacy threshold; AstraZeneca discontinued the trial. Monalizumab development refocused on NSCLC (PACIFIC-9, NeoCOAST-2).
IPH5201 + durvalumab + platinum chemo in resectable NSCLC showed pathological complete response of 35.7% (PD-L1>=1%) and 50% (PD-L1>=50%), exceeding the durvalumab+chemo benchmark; supports continued investigation of the AZ-optioned asset.
Per Innate's Q1 2026 update, Phase 3 PACIFIC-9 (durvalumab + monalizumab or oleclumab, unresectable Stage III NSCLC) enrollment is complete with a data readout expected in H2 2026 - the key catalyst for the monalizumab leg of the deal.
Monalizumab in Phase II/III combinations. First-in-class NKG2A mechanism. IPH5201 also advancing.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Innate Pharma SA (this deal) | 2018 | $1.3B | 54 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2018 deals · AstraZeneca PLC deals · Oncology deals